Scroll Up
Scroll Down
Play Play Play Play
Unregistered User
Click here if this is not your Personal Edition
 
Contact Us | Free E-Mail Updates | Journals | Register a colleague
 
 
Haematology Other
 
   
 
SEARCH   
Doctor's Guide Free CME
Medline
Congress Resource Centre
 

 EXPLORE :
   Most Read News
 All News  All News
 All Webcasts / CME  All Webcasts / CME
 All Cases  All Cases
 Congress Resource Centre  Congress Resource Centre
 All Medical Resources  All Medical Resources
 Medical  My Personal Edition



Warning | Privacy

 

 
 Recent news - Haematology Other
    Romiplostim Improves Platelet Counts in Nonsplenectomised Patients With Immune Thrombocytopenia: Presented at EHA - (DGDispatch)
    Eltrombopag Superior to Placebo for Patients With Previously Treated Chronic Idiopathic Thrombocytopenic Purpura: Presented at EHA - (DGDispatch)
    Use of Mycophenolate Mofetil Associated With Pure Red Cell Aplasia, Warns Health Canada - (DGNews)
    Experts Reach Consensus on Diagnosis, Treatment of Bleeding Disorders in Women - (DGNews)
    Teicoplanin Safe, as Effective as Vancomycin for Treating Patients With Febrile Neutropenia: Presented at ECCMID - (DGDispatch)

    News archive

     Recent webcasts/CME - Haematology Other

    Webcasts/CME archive

     Recent cases - Haematology Other
      A Diagnostic Difficulty: Two Cases of Haemophagocytic Syndrome in Adults
      Non ST-segment Elevation Myocardial Infarction in Patient with Essential Thrombocythemia
      Redo Aortic Valve Replacement After Partial Upper Sternotomy (Hemisternotomy) in a Patient with Idiopathic Thrombocytopenia: A Case Report
      Prolonged Hemophagocytic Lymphohistiocytosis Syndrome as an Initial Presentation of Hodgkin Lymphoma: A Case Report
      Hemolysis and Hyperhomocysteinemia Caused by Cobalamin Deficiency: Three Case Reports and Review of the Literature

      Cases archive
        




      my personal edition > haematology other > news
      divider

        E-Mail this DGNews to a colleague

      DGNews


      Amgen Updates Product Prescribing Information for Aranesp (darbepoetin alfa)

      BETHESDA, MD -- December 2, 2005 -- Amgen Inc. is informing health care professionals that sections of the product prescribing information for Aranesp (darbepoetin alfa) have been updated regarding the fact that, recently, pure red cell aplasia (PRCA) and severe anemia, with or without other cytopenias, associated with neutralizing antibodies to erythropoietin have been reported in patients treated with Aranesp.

      This new information is contained in the Warnings, Adverse Reactions, and Dosage and Administration sections.

      When utilized in accordance with the approved prescribing information, the benefit/risk profile of Aranespcontinues to be favorable.

      As the potential for PRCA and anti-erythropoietin antibody-associated severe anemia applies to all marketed erythropoietic proteins, product labeling for all drugs in this class have been updated in a consistent manner to state the following:

      1. If a patient develops a sudden loss of response, accompanied by severe anemia and low reticulocyte count, an evaluation for causative factors should be undertaken. If anti-erythropoietin antibody-associated anemia is suspected, physicians should withhold Aranesp® and other erythropoietic proteins and contact Amgen (1-800-77AMGEN) to perform assays for binding and neutralizing antibodies.

      2. Aranesp® should be permanently discontinued in patients with antibody-mediated anemia.

      3. Patients should not be switched to other erythropoietic proteins, as there is a potential for the antibodies to cross-react.

      Specifically, the revised sections of the label are as follows, with new information italicized:

      Warnings
      Pure Red Cell Aplasia

      Cases of pure red cell aplasia (PRCA) and of severe anemia, with or without other cytopenias, associated with neutralizing antibodies to erythropoietin have been reported in patients treated with Aranesp®. This has been reported predominantly in patients with CRF receiving Aranesp® by subcutaneous administration. Any patient who develops a sudden loss of response to Aranesp®, accompanied by severe anemia and low reticulocyte count, should be evaluated for the etiology of loss of effect, including the presence of neutralizing antibodies to erythropoietin (see PRECAUTIONS: Lack or Loss of Response to Aranesp®). If anti-erythropoietin antibody-associated anemia is suspected, withhold Aranesp® and other erythropoietic proteins. Contact Amgen (1-800-77AMGEN) to perform assays for binding and neutralizing antibodies. Aranesp® should be permanently discontinued in patients with antibody-mediated anemia. Patients should not be switched to other erythropoietic proteins as antibodies may cross-react (see ADVERSE REACTIONS: Immunogenicity).

      Adverse Reactions
      Immunogenicity
      As with all therapeutic proteins, there is a potential for immunogenicity. Neutralizing antibodies to erythropoietin, in association with PRCA or severe anemia (with or without other cytopenias), have been reported in patients receiving Aranesp® (see WARNINGS: Pure Red Cell Aplasia) during post-marketing experience.

      In clinical studies, the percentage of patients with antibodies to Aranesp® was examined using the BIAcore assay. Sera from 1501 CRF patients and 1159 cancer patients were tested. At baseline, prior to Aranesp® treatment, binding antibodies were detected in 59 (4%)of CRF patients and 36 (3%) of cancer patients. While receiving Aranesp® therapy (range 22-177 weeks), a follow-up sample was taken. One additional CRF patient and eight additional cancer patients developed antibodies capable of binding Aranesp®. None of the patients had antibodies capable of neutralizing the activity of Aranesp® or endogenous erythropoietin at baseline or at end of study. No clinical sequelae consistent with PRCA were associated with the presence of these antibodies.

      The incidence of antibody formation is highly dependent on the sensitivity and specificity of the assay. Additionally, the observed incidence of antibody (including neutralizing antibody) positivity in an assay may be influenced by several factors including assay methodology, sample handling, timing of sample collection, concomitant medications, and underlying disease. For these reasons, comparison of the incidence of antibodies across products within this class (erythropoietic proteins) may be misleading.

      Dosage and Administration
      Chronic Renal Failure Patients
      Aranesp® is administered either IV or SC as a single weekly injection. In patients on hemodialysis, the IV route is recommended. The dose should be started and slowly adjusted as described below based on hemoglobin levels. If a patient fails to respond or maintain a response, this should be evaluated (see WARNINGS: Pure Red Cell Aplasia, Precautions: Lack or Loss of Response to Aranesp® and PRECAUTIONS: Laboratory Tests). When Aranesp® therapy is initiated or adjusted, the hemoglobin should be followed weekly until stabilized and monitored at least monthly thereafter.

      There is no change in the Dosage and Administration section of the Aranesp® prescribing information for cancer patients.

      Health care professionals are encouraged to report adverse patient experiences in association with any Amgen product to Amgen's Medical Information Connection™ at 1-800-77-AMGEN or online at http://www.amgenmedinfo.com. Alternatively, this information may be reported to FDA's MedWatch reporting system by phone (1-800-FDA-1088), facsimile (1-800-FDA-0178), the MedWatch website (https://www.accessdata.fda.gov/scripts/medwatch), or mail to MedWatch, 5600 Fishers Lane Rockville, MD 20852-9787. Both health care professionals and consumers should use Form 3500 (available at the MedWatch website) for reporting adverse events.

      Questions or further information regarding the use of Aranesp® should be addressed to Amgen's Medical Information Connection™ at 1-800-77-AMGEN or online at http://www.amgenmedinfo.com.


      SOURCE: Amgen Inc.



      E-Mail this DGNews to a colleague   To print, use this version






      All contents Copyright (c) 1995-2009 Doctor's Guide Publishing Limited. All rights reserved.



      The NTK initiative. Physicians helping physicians identify Need-To-Know science
         Feedback
      Please rate this article: Strongly DISAGREE...Strongly AGREE NTK logo
      Question 1 - Physicians need to become aware of this information as soon as possible. Question 2 - This information is likely to have an impact on the way physicians practice medicine.
      1
      2
      3
      4
      5
      6
      7
      Send